CTT Pharma buys 3,000 shares at $0.0489

CTT PHARMACEUTICAL HOLDINGS, INC. reported a small open-market share purchase, bringing its directly held position to over 9.3 million shares.

Rhea-AI Filing Summary

CTT PHARMACEUTICAL HOLDINGS, INC. (CTTH) reported that it purchased 3,000 shares of its CTTH security on September 2, 2026, in a non-derivative open market or private transaction at a price of $0.0489 per share. Following this purchase, the reporting holder directly owns 9,387,256 shares.

No Rule 10b5-1 trading plan is reported for this transaction.

Insider Trade Summary

Net Buyer: 3,000 shares

Net Buy 1 txn

Insider CTT PHARMACEUTICAL HOLDINGS, INC.

Role CEO

Bought 3,000 shs ($146.70)

Type	Security	Shares	Price	Value
Purchase	CTTH	3,000	$0.0489	$146.70

Holdings After Transaction: CTTH — 9,387,256 shares (Direct)

Key Figures

Shares purchased: 3,000 shares Purchase price per share: $0.0489 per share Total shares after transaction: 9,387,256 shares +1 more

4 metrics

Shares purchased 3,000 shares Non-derivative CTTH purchase on September 2, 2026

Purchase price per share $0.0489 per share CTTH shares bought on September 2, 2026

Total shares after transaction 9,387,256 shares Directly owned CTTH shares following the reported purchase

Rule 10b5-1 plan status No Rule 10b5-1 plan reported Form-level checkbox for the reported transactions

Key Terms

non-derivative, direct ownership, Rule 10b5-1

3 terms

non-derivative financial

"The transaction involves a non-derivative security identified as CTTH"

direct ownership financial

"The filing reports direct ownership of 9,387,256 shares after the trade"

Rule 10b5-1 regulatory

"No Rule 10b5-1 trading plan is reported for this transaction"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

What insider transaction did CTTH report in this Form 4?

CTT PHARMACEUTICAL HOLDINGS, INC. reported a purchase of 3,000 CTTH shares on September 2, 2026, in a non-derivative open market or private transaction at $0.0489 per share.

How many CTTH shares are held after the reported transaction?

After the reported transaction, the filing shows 9,387,256 CTTH shares held with direct ownership by the reporting holder.

Was the CTTH insider trade made under a Rule 10b5-1 plan?

No. The filing indicates the Rule 10b5-1 checkbox is not affirmed, so no Rule 10b5-1 trading plan is reported for this transaction.

What was the price paid per share in the CTTH insider purchase?

The reported transaction price was $0.0489 per CTTH share for the purchase of 3,000 shares on September 2, 2026.

Is the reported CTTH transaction a derivative or non-derivative security?

The filing classifies the September 2, 2026 transaction as involving a non-derivative security, identified as CTTH, meaning it relates to the underlying security itself rather than options or other derivatives.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/02/2026 - 02:34 PM Accepted by SEC EDGAR 09/02/2026 - 02:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CTT PHARMACEUTICAL HOLDINGS, INC.

(Last) (First) (Middle)

1646 W. SNOW AVE SUITE 138

(Street)

TAMPA FLORIDA 33606

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CTT PHARMACEUTICAL HOLDINGS, INC. [ CTTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
CTTH	09/02/2026		P		3,000	A	$0.0489	9,387,256	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Ryan Khouri	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)